Ulcerative colitis treatment follows a tiered approach based on how severe your symptoms are and how much of the colon is affected. Mild disease often responds to anti-inflammatory medications alone, while moderate-to-severe cases typically require biologic drugs, small molecule therapies, or surgery. The goal of treatment has shifted in recent years: rather than simply controlling symptoms, doctors now aim for complete healing of the intestinal lining, which lowers the risk of flares and long-term complications.
Anti-Inflammatory Medications for Mild Disease
The first-line treatment for mild-to-moderate ulcerative colitis is a class of drugs called 5-ASAs (aminosalicylates). These medications work directly on the lining of the colon to reduce inflammation. They come in oral tablets, suppositories, and enemas, and your doctor may recommend combining oral and rectal forms for better coverage. For maintenance, doses of at least 2 grams per day have shown the most consistent benefit in preventing relapse.
5-ASAs are effective for many people with limited or mild disease, but they have a ceiling. The American Gastroenterological Association now suggests that patients with moderate-to-severe disease who have already failed on 5-ASAs should stop them entirely once they’ve moved on to stronger therapies, rather than stacking medications unnecessarily.
Corticosteroids: Short-Term Rescue, Not Long-Term Solution
When a flare hits hard, corticosteroids like prednisone can bring inflammation down quickly. They’re effective at inducing remission but are not safe or useful for maintaining it over time. British guidelines typically recommend starting at 40 mg of prednisolone and tapering over 6 to 8 weeks, while American guidelines suggest tapers over 8 to 12 weeks. Recent evidence supports shorter tapers (around 6 weeks) for patients discharged after a severe flare, with close monitoring afterward.
The risks of prolonged steroid use are substantial. Bone density loss, including osteoporosis, affects a significant number of patients with inflammatory bowel disease who stay on steroids. Mood disturbances occur in up to 60% of patients on corticosteroids, with roughly 5% experiencing serious psychiatric symptoms. Other complications include elevated blood sugar (with diabetes risk proportional to dose and duration), high cholesterol, fatty liver, increased susceptibility to infections, and muscle weakness. Because of these risks, a key treatment milestone is achieving “steroid-free remission,” meaning your disease stays quiet without needing steroids at all.
Biologics for Moderate-to-Severe Disease
Biologic therapies are lab-engineered proteins that target specific parts of the immune system driving inflammation. They represent the backbone of treatment for moderate-to-severe ulcerative colitis and fall into several categories based on what they block.
TNF blockers were the first biologics available and remain widely used. Infliximab is given by IV infusion every several weeks, while adalimumab and golimumab are self-administered injections. The AGA classifies infliximab as a higher-efficacy option and recommends combining TNF blockers with an immunomodulator drug for better results. Adalimumab, by contrast, is now considered lower-efficacy compared to newer options.
Vedolizumab takes a different approach, targeting immune cells specifically headed to the gut rather than suppressing the immune system broadly. This gut-selective mechanism can mean fewer systemic side effects. It’s classified as a higher-efficacy option for patients who haven’t tried advanced therapies before.
Newer biologics target different inflammatory pathways. Ustekinumab blocks two immune signaling molecules involved in driving colitis. Risankizumab and guselkumab, both newer entries, are classified as higher-efficacy options for treatment-naive patients. Mirikizumab represents yet another mechanism. For patients who have already tried and failed a TNF blocker, the AGA suggests choosing from a different group: ustekinumab, risankizumab, guselkumab, or the small molecule options described below tend to work better in that situation than switching to another TNF blocker.
Small Molecule Oral Therapies
Unlike biologics, which are large protein molecules that must be injected or infused, small molecule drugs are pills taken by mouth. Two main classes are now approved for ulcerative colitis.
JAK inhibitors (tofacitinib, upadacitinib, and filgotinib) work by blocking enzymes inside immune cells that relay inflammatory signals. Upadacitinib and tofacitinib are classified as higher-efficacy choices for patients who’ve already failed a biologic. These drugs act relatively fast compared to some biologics, but they carry specific risks your doctor will discuss, particularly regarding infections and blood clots.
S1P receptor modulators (ozanimod and etrasimod) work by trapping certain immune cells in lymph nodes so they can’t travel to the colon and cause inflammation. Both are considered higher-efficacy for treatment-naive patients. The oral convenience of all these small molecules is a practical advantage for people who prefer not to deal with injections or infusion appointments.
Early Escalation Over Step-Up
Treatment guidelines have shifted meaningfully in recent years. The older approach was gradual step-up: start with the mildest therapy and only escalate when it fails. The AGA now suggests early use of advanced therapies or immunomodulators for moderate-to-severe disease rather than waiting for 5-ASAs to fail. The reasoning is straightforward. Uncontrolled inflammation causes cumulative damage to the colon, and earlier intervention with effective drugs leads to better long-term outcomes. If you’re newly diagnosed with moderate-to-severe disease, your doctor may recommend starting with a biologic or small molecule right away.
Treatment Goals: Mucosal Healing
Feeling better is important, but the deeper treatment target is mucosal healing, meaning the colon lining looks normal on a colonoscopy. Doctors assess this using the Mayo Endoscopic Subscore, a 0-to-3 scale where 0 means normal mucosa and 3 means spontaneous bleeding and ulcers. Earlier clinical trials accepted a score of 0 or 1 as “healed,” but the current standard has tightened to a score of 0 only. Patients who achieve a score of 0 have considerably lower relapse rates than those at a score of 1, both in the short and long term.
Between colonoscopies, a stool test called fecal calprotectin helps track inflammation without an invasive procedure. A level below 60 micrograms per gram reliably indicates a quiet, healed colon. Levels between 110 and 310 suggest increasing degrees of active inflammation, and readings above 310 point to severe disease. Many gastroenterologists use this test every few months to catch rising inflammation before symptoms return.
Surgery
About 15% to 30% of people with ulcerative colitis eventually need surgery, which involves removing the entire colon and rectum. Surgery is considered in three main scenarios: emergencies like perforation or uncontrolled bleeding, failure to maintain an acceptable quality of life despite aggressive medical therapy, and situations where medications are controlling the colitis but causing intolerable side effects.
The most common procedure today is the ileal pouch-anal anastomosis, often called J-pouch surgery. The surgeon removes the colon and rectum, then fashions a pouch from the end of the small intestine and connects it to the anus. This preserves the natural route for bowel movements and avoids a permanent external bag. Most patients report good quality of life afterward, typically having 4 to 8 bowel movements per day once fully healed.
For some patients, a permanent ileostomy (where the small intestine empties into an external pouch on the abdomen) remains the better choice, particularly for those with poor sphincter function or who prefer not to undergo the more complex pouch procedure. Because surgery removes the entire diseased organ, it is the only true cure for ulcerative colitis, though life after surgery involves its own adjustments.
Diet and Lifestyle
No diet can replace medication for controlling ulcerative colitis, but dietary changes can meaningfully reduce day-to-day symptoms. A low-FODMAP diet, which limits certain fermentable carbohydrates found in foods like wheat, onions, garlic, and some fruits, has been shown to reduce abdominal pain, bloating, and gas in people with inflammatory bowel disease. In a meta-analysis of clinical trials, patients on a low-FODMAP diet were nearly 3 times more likely to experience reduced bloating and over 5 times more likely to report less flatulence compared to controls. Quality of life scores also improved.
However, the low-FODMAP diet did not change actual disease activity or inflammation levels in ulcerative colitis. It helps with the functional, irritable-bowel-like symptoms that often overlap with colitis, not the underlying disease itself. Working with a dietitian who understands IBD is valuable, both for implementing a low-FODMAP approach correctly and for ensuring you’re not missing key nutrients during flares when appetite and absorption are compromised.
Fecal Microbiota Transplant
Fecal microbiota transplant (FMT), which involves introducing stool from a healthy donor into the colon to restore microbial balance, has shown real promise for ulcerative colitis. A meta-analysis of 13 randomized controlled trials found that FMT patients were 73% more likely to achieve clinical remission than controls, with similar improvements in endoscopic healing. The procedure’s safety profile was comparable to placebo, with no significant increase in adverse events.
That said, FMT is not yet a standard treatment for ulcerative colitis. Maintaining long-term remission after transplant remains a challenge, and the amount of transplanted material appears to affect how well it works. The technique has matured considerably since 2018, with better donor screening and delivery methods improving outcomes, but it’s still primarily available through clinical trials or specialized centers.